Sitagliptin and Metformin vs Linagliptin — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Dipeptidyl Peptidase 4 Inhibitor

Sitagliptin and Metformin

Brand: JANUMET

First FDA approval: 2007-03-30

Dipeptidyl Peptidase 4 Inhibitor

Linagliptin

Brand: Tradjenta

First FDA approval: 2011-05-09

Lowest NADACAcquisition cost floor across all NDCs

$5.03Per unit

$16.80Per unit

Average NADACAcross all dosage forms and strengths

$6.33Up to $10.56

$16.80Up to $16.80

Generic manufacturersActive ANDA holders — FDA Orange Book

12 total ANDAs filed

77 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

—Full year

$1.64BFull year

Part D claims (CY24)Total fills, all strengths

—— beneficiaries

2.1M486K beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

—Per claim, all NDCs

$782Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

5Minimal friction

1Minimal friction

Step therapy appliedPlan-NDC pairs requiring step therapy

0None

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

Generic availableFDA Orange Book

Yes1 manufacturers

Yes7 manufacturers